AbbVie's (ABBV) Allergan Submits NDA to FDA for AGN-190584 to Treat Presbyopia

Go back to AbbVie's (ABBV) Allergan Submits NDA to FDA for AGN-190584 to Treat Presbyopia

Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia

February 25, 2021 8:00 AM EST

NORTH CHICAGO, Ill., Feb. 25, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021.

Approximately 128 million adults in the U.S. experience presbyopia, a common and progressive eye condition that reduces the eye's ability to focus on near objects and usually impacts people after age 40. Yet, compared to other... More